- Home
- BAFN vs COEP Comparison
BAFN vs COEP Comparison
Compare BAFN & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- COEP
- Stock Information
- Founded
- BAFN 1999
- COEP 2017
- Country
- BAFN United States
- COEP United States
- Employees
- BAFN N/A
- COEP N/A
- Industry
- BAFN Savings Institutions
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BAFN Finance
- COEP Health Care
- Exchange
- BAFN Nasdaq
- COEP Nasdaq
- Market Cap
- BAFN 63.2M
- COEP 62.4M
- IPO Year
- BAFN N/A
- COEP N/A
- Fundamental
- Price
- BAFN $8.51
- COEP $12.71
- Analyst Decision
- BAFN
- COEP
- Analyst Count
- BAFN 0
- COEP 0
- Target Price
- BAFN N/A
- COEP N/A
- AVG Volume (30 Days)
- BAFN 21.9K
- COEP 39.8K
- Earning Date
- BAFN 10-23-2025
- COEP 11-12-2025
- Dividend Yield
- BAFN 3.79%
- COEP N/A
- EPS Growth
- BAFN 100.65
- COEP N/A
- EPS
- BAFN 1.89
- COEP N/A
- Revenue
- BAFN $78,211,000.00
- COEP $263,555.00
- Revenue This Year
- BAFN N/A
- COEP N/A
- Revenue Next Year
- BAFN N/A
- COEP N/A
- P/E Ratio
- BAFN $4.48
- COEP N/A
- Revenue Growth
- BAFN 0.67
- COEP N/A
- 52 Week Low
- BAFN $6.40
- COEP $2.31
- 52 Week High
- BAFN $19.75
- COEP $14.70
- Technical
- Relative Strength Index (RSI)
- BAFN 38.42
- COEP 51.96
- Support Level
- BAFN $8.40
- COEP N/A
- Resistance Level
- BAFN $8.77
- COEP $13.13
- Average True Range (ATR)
- BAFN 0.33
- COEP 0.69
- MACD
- BAFN 0.15
- COEP -0.58
- Stochastic Oscillator
- BAFN 12.70
- COEP 92.44
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.